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Abstract: Targeted therapies, such as radioimmunotherapy (RIT), present a promising treatment option
for the eradication of tumor lesions. RIT has shown promising results especially for hematologic
malignancies, but the therapeutic efficacy is limited by unfavorable tumor-to-background ratios
resulting in high radiotoxicity. Pretargeting strategies can play an important role in addressing the
high toxicity profile of RIT. Key to pretargeting is the concept of decoupling the targeting vehicle from
the cytotoxic agent and administrating them separately. Studies have shown that this approach has
the ability to enhance the therapeutic index as it can reduce side effects caused by off-target irradiation
and thereby increase curative effects due to higher tolerated doses. Pretargeted RIT (PRIT) has been
explored for imaging and treatment of different cancer types over the years. This review will give an
overview of the various targeted therapies in which pretargeting has been applied, discussing PRIT
with alpha- and beta-emitters and as part of combination therapy, plus its use in drug delivery systems.
Keywords: pretargeting; radioimmunotherapy; targeted radionuclide therapy; cancer; streptavidin;
biotin; bispecific antibody; oligonucleotides; click chemistry; nanoparticles
1. Introduction
Within nuclear medicine, target mediated radionuclide interventions have emerged as powerful
tools for noninvasive molecular imaging and therapy of cancer. Antibodies have been established as
potent vectors for delivery of radioactivity because of their high affinity and specificity towards target
antigens. A primary concern of the use of radiolabeled antibodies is their slow pharmacokinetics, i.e.,
a low tumor penetration and low excretion rate [1]. Due to the long residence time of antibodies in the
bloodstream, it takes a long time to achieve adequate tumor-to-background ratios after radiotracer
injection. For this reason, the use of long-lived radionuclides is required. Besides the dose to the tumor,
this results in high effective radiation doses to healthy tissue, in particular, the bone marrow. Clinical
complications can occur as a consequence of healthy tissue irradiation, especially when repeated
imaging procedures or high therapeutic doses are necessary. Over the past decades, new targeting
strategies have been developed to overcome the pharmacokinetic drawbacks caused by the large size
of antibodies. One proposed strategy is the use of antibody fragments or engineered antibody formats
to enhance tissue penetration. Although this attempt can be successful, it was also observed that a
decrease in size is often associated with a lower binding affinity which leads to reduced radioactivity
uptake in the tumor [2].
An alternative approach is based on separating the antibody from the radionuclide and letting the
two agents combine in vivo [3,4]. This so-called pretargeting concept basically consists of three steps
(Figure 1A). In step 1, the targeting vector designed to bind both the target antigen and a radiolabeled
small molecule is injected. Once accumulated at the target site and largely cleared from the blood
(step 2), a complementary radiolabeled small molecule is administered (step 3). Upon encountering the
targeting vector, ligation will take place between the two molecules which leads to the in vivo formation
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of the radioimmunoconjugate. Due to the small size of the secondary agent, it possesses favorable
pharmacokinetic properties, hence the remaining radiolabeled small molecules are rapidly excreted.
Occasionally, an extra step with a clearing agent is introduced to remove the unbound targeting vector
from the circulation before the injection of the radiolabeled small molecule. The respective clearing
agent roughly consists of a binding motif for the pretargeting moiety and a carbohydrate with high
affinity for the liver. After injection of the clearing agent, the molecule will rapidly bind the targeting
vector, and the newly formed complex will be excreted via hepatic catabolism. The pretargeting
strategy thus allows administration of the radiolabeled substance at optimal tumor-to-non tumor
(T:NT) ratios, thereby significantly lowering healthy tissue irradiation.
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Figure 1. The pretargeting concept. (A) Different steps of the pretargeting approach. The targeting 
vector consists of a binding domain, a linker, and a pretargeting moiety (dark blue) and the small 
molecule of a complementary pretargeting moiety, a linker, and an effector (e.g., a radionuclide) (light 
blue). (B) The four most commonly applied pretargeting methods are illustrated with an antibody as 
target vector and a radionuclide as effector. I) The streptavidin–biotin approach. The dotted circles 
represent the other three biotin binding sites of (strept)avidin. II) Pretargeting using bispecific 
antibodies with a binding site for a radiolabeled hapten. Two small molecules are shown with on the 
left a monovalent hapten and on the right a bivalent hapten that could bridge two antibodies (i.e., 
affinity enhancement system). III) Pretargeting based on oligonucleotide hybridization. The backbone 
can for example exist of morpholine rings (i.e., MORF/cMORF pretargeting). IV) The click chemistry 
technology. A covalent bond-forming approach between, for example, trans-cyclooctene and 
tetrazine. 
The success of this method is fully dependent on the formation of strong chemical interactions 
between the complementary reactive groups coupled to the targeting vector and the radiolabeled 
small molecule under the physiological conditions present in the body. Several bioconjugation 
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with established high binding constants and fast binding kinetics have been studied for pretargeting
purposes. Four pretargeting methods are commonly applied (Figure 1B). The avidin–biotin system
is based on the strongest noncovalent biological interaction known between biotin and avidin or
streptavidin (SA), which possesses four binding sites for radiolabeled biotin molecules [5]. Roughly
in the same period, bispecific antibodies with one arm directed against the tumor antigen and one
against a radiolabeled hapten (e.g., indium-labeled diethylenetriaminepentaacetic acid (In-DTPA) and
histidine-succinyl-glycine (HSG) peptide) were developed [6]. Due to low tumor activity uptake, the
use of a bivalent hapten was suggested so that the bispecific antibodies could be crosslinked at the cell
surface resulting in binding with enhanced affinity. For this reason, this method is known as the affinity
enhancement system [7]. A few years later, a pretargeting method based on the hybridization of an
oligonucleotide conjugated to an antibody and a radiolabeled complementary oligonucleotide was
generated [8]. In order to enhance the in vivo stability of the oligonucleotides, Liu et al. introduced the
use of morpholino backbones (i.e., MORF/cMORF pretargeting) [9]. Bioorthogonal click chemistry was
most recently considered as an effective pretargeting strategy, because it exploits pairs of functional
groups that rapidly, selectively, and covalently bind in biological systems. One of the proposed
click chemistry techniques is the inverse electron demand Diels–Alder (IEDDA) cycloaddition of
trans-cyclooctene (TCO) and tetrazine (Tz) which was first introduced in 2010 by Rossin et al. for
pretargeted tumor imaging [10]. The mechanisms, advantages, and limitations of each bioconjugation
methodology for pretargeting purposes have been extensively discussed in previous reviews [11–14].
Originally, the use of pretargeting was evaluated for nuclear imaging to improve both contrast
and safety. Moreover, it enables the use of radionuclides with shorter half-lives which were otherwise
not compatible with the long circulation time of antibodies. However, pretargeting is conjointly very
interesting for therapy. It has the ability to enhance the therapeutic index by reducing side effects
caused by off-target irradiation and thereby increase curative effects due to higher tolerated doses.
Over time, the scope of pretargeting had broadened even further, and next to radionuclide imaging
and therapy, this strategy has also been studied for application of other anticancer treatments such
as chemotherapeutics.
In this paper, we will provide an overview of the various therapies in which pretargeting strategies
have been applied over the years and how it has emerged for each target and purpose. Furthermore,
we will discuss novel applications of pretargeting, specifically alpha-particle therapy, combination
therapy, and drug delivery.
2. Pretargeted Radioimmunotherapy with Beta-Emitting Radionuclides
Treatment using tumor targeting antibodies labeled with cytotoxic radionuclides is called
radioimmunotherapy (RIT). RIT is an interesting treatment option for tumor lesions that cannot
be surgically removed or easily eradicated by external beam radiation therapy. Since RIT is often
associated with high toxicity profiles, the pretargeting strategy has been investigated to improve RIT
for both hematologic and solid cancers.
2.1. Hematologic Cancers
Although RIT is clinically proven to have a significant antitumor effect in radiosensitive hematologic
malignancies such as non-Hodgkin lymphoma (NHL) [15–17], the therapeutic efficacy is still limited
by the maximum dose that can be safely administered. The bone marrow is usually the dose-limiting
organ. Therefore, the pretargeting strategy has been studied for safe and effective RIT directed against
various hematological tumor antigens, including CD20, CD45, and CD38.
2.1.1. CD20 Antigen
Since CD20 is highly expressed on lymphomas, CD20-directed RIT has been studied for treatment
of this cancer type. Radiolabeled anti-CD20 antibodies have shown promising results in patients with
relapsed or refractory B-cell lymphoma. However, the majority of patients presented recurrent disease
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after treatment, indicating the need for higher tumor doses. To increase therapeutic efficacy while keeping
toxicity levels low, pretargeted RIT (PRIT) targeting CD20 antigens has been evaluated in preclinical and
clinical studies. In a preclinical study, Press et al. compared RIT and PRIT using yttrium-90 with respect
to dose and toxicity in mice bearing human lymphoma xenografts [18]. The authors demonstrated that
the RIT doses required for significant tumor responses were associated with lethal toxicity in 100%
of the animals, while PRIT with a tolerable two-fold higher dose cured 89% of mice. A comparative
study performed by Subbiah et al. produced similar results whilst even showing a cure rate of 100%
with PRIT [19]. A clinical phase I/II study with CD20-directed PRIT was published by Weiden et al. in
2001 [20,21]. In this study, performed in relapsed NHL patients, pretargeting also resulted in superior
tumor-to-whole body dose ratios when compared to other studies using conventional RIT. Moreover,
tumor responses were encouraging as tumors regressed in 6/7 patients treated with PRIT.
In the above studies, pretargeting was performed via the avidin–biotin system. Although results
were positive when compared to RIT, patients developed an immune response to SA after treatment.
To overcome this problem, a different pretargeting method making use of bispecific antibodies (bsAbs)
was explored for CD20 targeting. Comparison of directly labeled anti-CD20 IgG vs. an anti-CD20 ×
anti-HSG bsAb pretargeting system both labeled with yttrium-90 showed a therapeutic advantage of
the latter either when given as a single injection or as fractionated doses [22]. The therapeutic index was
even better when a recombinant bsAb was used instead of a chemically conjugated bsAb. Specifically, a
2.6-fold increased tumor uptake and >45-fold improved tumor-to-blood (T:B) ratio were observed [23].
In a second attempt to overcome immunogenicity, engineered fusion proteins (FPs) were applied
for CD20-directed PRIT. FPs consist of single or multiple single chain variable fragments (scFv) directed
against a specific tumor antigen, that are coupled to SA (scFvSA). Initial preclinical proof-of-concept of
such a construct in a PRIT setting was advanced by Schultz et al. who designed and successfully tested
an FP based on the CD20-directed antibody B9: a tetravalent scFvSA (scFv4SA) [24]. This genetically
engineered FP labeled with yttrium-90 was also successfully applied in a clinical pilot study in a NHL
patient [25]. Additionally, a phase I trial was performed using this same FP for pretargeting [26]. This
study resulted in a tumor-to-whole body dose ratio of 49:1, significantly higher than the reported 38:1
ratio for the SA-conjugated anti-CD20 antibody in the clinical study of Weiden et al. [21]. A direct
comparison of a SA-conjugated anti-CD20 antibody 1F5 and a FP for pretargeting based on the same
antibody in human lymphoma bearing mice revealed similar tumor uptakes. However, better T:B ratios
were obtained with the FP than the antibody conjugate (>65:1 vs. <7:1) [27]. In another study by Green
et al., favorable biodistribution of a FP based on the CD20-directed antibody 2H7 was confirmed [28].
Moreover, the authors demonstrated that the pretargeting strategy using this FP and yttrium-90-labeled
biotin was highly effective, since all human lymphoma-bearing animals were cured and considerably
less myelosuppression was observed.
Alternatively, mutant SA and bis-biotin carriers were used to evade SA immunogenicity and
interference of endogenous biotin, which is also a complication of the avidin–biotin system [29].
The application of engineered mutant SA FPs and yttrium-90-labeled bis-biotin reagents enhanced the
antitumor efficacy. Mice bearing human lymphoma xenografts treated with the most potent mutant SA
FP determined by this study and wild-type SA FP had average tumor volumes of 237 ± 66 mm3 and
1129 ± 322 mm3 after 11 days, respectively [30]. Frost et al. showed that the therapeutic efficacy is also
influenced by the choice of radionuclide. Comparison of lutetium-177 and yttrium-90 for anti-CD20
PRIT showed that a more than two-fold higher absorbed radiation dose could be delivered to a B-cell
neoplasm when pretargeting was performed with yttrium-90 instead of lutetium-177 [31].
2.1.2. Other Hematological Tumor Targets
B-cell lymphoma 1 protein (BCL1)-directed PRIT was explored for mantle cell lymphomas as
approximately 35–66% of this lymphoma subtype expresses BCL1 [32]. In an initial preclinical study,
the use of a pretargeting system based on the anti-BCL1 × anti-HSG bsAb and a complementary
iodine-131 bivalent hapten resulted in survival of 14/16 mice without severe toxicity, while directly
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labeled antibodies induced death from acute toxicity in 3/16 mice [33]. This again demonstrates the
potential of PRIT to reduce toxicity. Next to CD20, CD22 and the human leukocyte antigen-DR have also
been investigated as targets in clinical RIT studies. For all antigens, it holds that PRIT is superior over
RIT in terms of biodistribution [34]. The success of the treatment, however, depends on the antigenic
expression which is different in each lymphoma cell line. Interestingly, no synergistic or additive benefit
was observed when a combination therapy of all three antibodies was given. In a pediatric anaplastic
large cell lymphoma patient, immunohistochemistry indicated the presence of tenascin and using this
target for PRIT with yttrium-90 resulted in a remarkable complete remission as the patient was resistant
to all other treatments [35].
In patients with acute myeloid leukemia (AML), RIT directed against the CD45 antigen has shown
encouraging results, making it an interesting target for this patient group. Lin et al. developed and
evaluated an anti-CD45 scFv4SA for PRIT of AML to overcome the limitations of RIT regarding high
toxicity and subsequent limited cure rates [36]. The preclinical study performed in mice bearing
CD45 positive human lymphoma xenografts resulted in 100% survival when treated with high dose
PRIT using yttrium-90. One major issue in preclinical anti-CD45 PRIT research concerns the use of
xenograft mouse models. Mouse hematopoietic cells lack CD45 expression, while in human subjects,
CD45 is expressed on tumors cells and hematopoietic cells. Therefore, Pagel et al. used a syngeneic
murine leukemia model in which normal myeloid, lymphoid, and reticuloendothelial tissues expressed
the CD45 antigen [37]. Therapy studies demonstrated high T:NT ratios and significantly prolonged
survival compared to conventional RIT in this model [38]. The therapeutic advantage of anti-CD45
PRIT was also shown in nonhuman primates [39], again suggesting that applying a pretargeting
strategy is superior to conventional RIT and even allows intensification of treatment schedules. Since
CD45 is stably expressed with high density on the majority of hematopoietic cells, CD45-directed
therapy can provide an alternative for CD20 negative lymphoma patients. A comparison was made
between anti-CD45 and anti-CD20 antibodies for PRIT in mice bearing human lymphoma xenografts
that were CD20 and CD45 positive [40]. Both anti-CD45 and anti-CD20 PRIT were effective, but
anti-CD45 antibodies resulted in the delivery of two- to four-fold more radiation to the tumor than the
anti-CD20 antibodies. It is likely due to the superior retention of this antibody on the cell surface.
In contrast to NHL and AML, very little attention has been paid to the role of RIT and even
PRIT in multiple myeloma (MM). The CD38 transmembrane glycoprotein retains at high density
and uniform expression on MM cells and is minimally expressed on normal hematopoietic cells.
In a preclinical study, anti-CD38-SA PRIT with yttrium-90 reached long-term myeloma-free survival
in all animals bearing human MM tumor xenografts and T:B ratios of 638:1 compared to <1:1 for
conventional RIT [41]. A direct comparison was made between two pretargeting strategies directed
against CD38, the streptavidin–biotin based approach and a bispecific FP developed to eliminate SA
related immunogenicity [42]. The results of this preclinical study showed that at the highest radiation
dose tested, cure rates for the two approaches were similar, while at lower doses the bispecific FP
outperformed CD38-SA.
2.2. Solid Cancers
In contrast to treatment of hematologic malignancies, RIT has failed to be effective for solid tumors
because of their lower radiosensitivity [43]. Moreover, in advanced stages where tumors are bulkier
and less vascularized, tumors are less accessible to antibodies resulting in limited tumor radioactivity
uptake and thus low T:NT ratios. These factors contribute to suboptimal therapeutic indexes since high
doses need to be administered to obtain a therapeutic effect. Furthermore, the bone marrow is, similar
to hematologic malignancies, also the dose-limiting organ for RIT in solid tumors. Introduction of
pretargeting strategies can provide a safe and effective approach for RIT of solid tumors. PRIT targeted
against several tumor antigens, including the carcinoembryonic antigen (CEA) and the tumor-associated
glycoprotein 72 (TAG-72), have been studied for treatment of solid tumors and will be discussed below.
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2.2.1. Carcinoembryonic Antigen (CEA)
CEA is one of the most widely used tumor markers. CEA is highly expressed in colorectal
carcinoma (CRC), medullary thyroid carcinoma (MTC), and small cell lung cancer (SCLC), with the
first two being the subject of many preclinical studies. A comparative study of the affinity enhancement
system (AES) with a murine anti-CEA × anti-DTPA-In bsAb and conventional RIT in a LS174T human
CRC animal model demonstrated the superiority of pretargeting [44]. Iodine-131 treatment with the
directly labeled antibody resulted in a growth delay of 53 ± 5 days while PRIT resulted in efficient
growth inhibition >150 days. Besides, a nearly 10-fold higher dose could be administered safely in
terms of both hematologic and nonhematologic toxicity. A direct comparison between this bsAb and
a bsAb with a humanized anti-CEA arm both labeled with rhenium-188 showed that the chimeric
antibody was cleared more rapidly from the blood because it was recognized by the reticuloendothelial
cells from the spleen [45]. However, the authors argued that this recognition mechanism may be unique
for the mouse model and will not be observed in clinical settings. Although a faster blood clearance
results in less tumor targeting, Yazaki et al. still observed that lutetium-177-based pretargeting reached
a much higher T:B ratio than the direct targeting approach, 199:1 vs. 3:1 respectively [46]. Karacay
et al. showed that higher doses could be tolerated with PRIT using fully humanized anti-CEA ×
anti-HSG bsAbs and yttrium-90-labeled haptens [47]. A 2.5-times higher tumor dose directly translated
into improved survival with 33% tumor ablation versus 100% tumor viability in the conventional
RIT treated animals bearing human CRC tumors. The same cure rate was reported by Gautherot et
al. when treating human CRC xenografted mice with PRIT using murine anti-CEA × anti-DTPA-In
bsAb and an iodine-131-labeled hapten [48]. The same pretargeting system has also been applied to
human MTC xenografted mice and this was compared to RIT using radiolabeled antibody fragments
consisting of two antigen-binding portions linked together (F(ab’)2) [49]. Both methods resulted in high
tumor uptake values of 8.0 and 7.39%ID/g at 24 h, respectively. However, a higher T:B ratio of 37:1 vs.
1.8:1 was observed for PRIT vs. RIT with iodine-125, respectively. Additionally, Kraeber-Bodéré et al.
showed less toxicity for the PRIT treatment group with iodine-131 [50].
CEA is the most extensively studied solid tumor target for PRIT purposes and a lot of research has
been performed to optimize conditions for anti-CEA PRIT. This includes preclinical studies regarding
the bsAb/hapten molar ratio injected and time interval between injections. The pretargeting efficacy is
an interplay between both pretargeting parameters. Gautherot et al. demonstrated that increasing
the delay between the injection of the anti-CEA × anti-DTPA-In bsAb and the iodine-131-labeled
bivalent hapten from 15 h to 20 h significantly reduced myelotoxicity caused by circulating activity [48].
Sharkey et al. showed that an anti-CEA × anti-HSG bsAb/indium-111-labeled hapten injection ratio
of 50:1 combined with a 48 h delay resulted in a 1.6-fold higher tumor uptake than a 10:1/24 h
combination [51]. The authors demonstrated that increasing the bsAb dose should be accompanied by
lengthening the time interval to maintain adequate T:B ratios. Alternatively, Mirallié et al. tested an
avidin chase to remove excess biotinylated bsAbs from the circulation before the hapten injection and
showed 3.5-fold improved T:B ratios [52].
Furthermore, studies have been performed to investigate whether the therapeutic efficacy of
anti-CEA PRIT can further be optimized by performing repeated treatments to reach curative doses.
The success of this strategy partly depends on the CEA expression levels after a single cycle of PRIT.
Immunohistological analysis showed that the CEA status remained unchanged in MTC tumors, but that
CRC lesions presented a 58% loss of CEA membrane expression [53]. The first study was performed by
Kraeber-Bodéré et al. who confirmed that repeated treatments of PRIT based on the AES with murine
anti-CEA × anti-DTPA-In bsAbs and iodine-131-labeled haptens in mice xenografted with human
MTC led to high antitumor efficiency without a significant increase in toxicity [54]. Generally, a longer
tumor response was achieved with the remarkable exception of two complete responses after two
therapy cycles. Successive cycles of anti-CEA × anti-HSG bsAb and lutetium-177-labeled hapten based
PRIT also effectively delayed the growth of human CRC tumors and enhanced survival from 13 to
65 days for mice treated with three cycles vs. one cycle of PRIT [55]. Interestingly, three cycles did
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not outperform two cycles (Figure 2), probably due to decreased tumor uptake during the third cycle
which might be caused by a lower CEA expression as previously reported.
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Not only can pretargeting parameters or the treatment schedule influence the therapeutic index,
but the pretargeting method also can. The chelator and the radionuclide of choice can play an important
role. In a LS174T human CRC ouse model, bivalent haptens labeled with various radionuclides (i.e.,
indium-111, yttrium-90 and iodine-131) against the anti-CEA × anti-DTPA-In BsF(ab’)2 proved to have
a higher targeting efficiency than the monovalent hapten [56]. Gestin et al. pointed out that the greater
range of rhenium-188 could be beneficial over iodine-131 for radiolabeling of haptens in the treatment of
larger CRC tumors with a diameter up to 1 cm [57]. Most preclinical anti-CEA PRIT studies have been
performed with the AES, but few are based on the avidin–biotin system. For this approach, higher T:NT
ratios were obtained when biotin was coupled to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA) instead of DTPA to complex yttrium-90 [58]. The MORF/cMORF pretargeting system also
led to promising results as anti-CEA PRIT with rhenium-188 ceased tumor growth after 1 day, contrary
to continued growth in the control group [59].
A lot of effort has been made to translate anti-CEA PRIT to the clinic. Already in 1996, Bardies et al.
performed a feasibility study using the pretargeting approach with murine anti-CEA × anti-DTPA-In
bsAbs and iodine-131-labeled bivalent haptens in 10 patients with MTC and SCLC [60]. Interestingly,
a higher uptake was detected in recurrences of MTC than of SCLC, even though CEA expression
levels of primary tumor biopsies (used as an inclusion criterion for the study) were similar. This could
indicate that CEA expression levels of the primary tumors are not predictive for expression levels in
recurrent disease. Hence, imaging beforehand could help to select eligible patients for PRIT. Using the
same pretargeting system, Chatal et al. demonstrated long-term efficacy in terms of survival benefit
in 29 patients with rapidly progressive metastatic MTC [61]. This study provided the first proof of
effective RIT in solid tumor patients with confirmed metastatic disease; however, here, a pretargeting
strategy was applied and essential for the observed success. It was determined that PRIT treated
patients with a serum calcitonin doubling time (Ct DT), a prognostic biomarker for survival in MTC, of
less than 2 years (high-risk group) had a significantly longer survival than the corresponding untreated
control group; 110 vs. 61 months, respectively.
Clinical translation can be hampered by the development of a significant human anti-mouse
antibody response. Ideally, such a response should be avoided and for this reason a phase I optimization
trial was initiated using a chimeric anti-CEA × anti-DTPA-In bsAb and iodine-131-labeled bivalent
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hapten [62]. A bsAb dose of 40 mg/m2 was preferred over 70 mg/m2 as it significantly decreased
the risk of severe hematologic toxicity. However, it came at the cost of therapeutic efficacy in terms
of the disease stabilization rate, 22% versus 64% respectively. Additionally, it was determined that
MTC patients possessed a higher risk of hematologic toxicity than patients with other CEA-expressing
tumors. This suggests that PRIT dose schedules should be altered for each tumor type. Serious
hematologic side effects of anti-CEA PRIT with iodine-131 were also observed in a phase II trial in
advanced and progressive MTC patients [63]. However, a high disease control rate of 76% was reached
and treatment appeared to be effective in patients with short Ct DTs, suggesting limiting the application
of PRIT to the poor prognostic risk group.
Despite the use of chimeric bsAbs, immunogenicity was still present and therefore efforts were
made to prepare fully humanized constructs. Pretargeting based on the new generation of humanized,
recombinant, trivalent anti-CEA × anti-HSG bsAbs named TF2 was shown to be safe for the treatment
of metastatic CRC patients with the lutetium-177-labeled hapten IMP288 [64]. Subsequent dosimetry
data based on a pretherapy diagnostic study where the hapten was labeled with indium-111 could
accurately predict the maximum tolerated dose in a PRIT situation [65]. The authors improved the
dosimetry model and predicted that tumor-to-bone marrow ratios would increase by an average of
25% when using yttrium-90 instead of lutetium-177 for therapy [66]. The new compounds were also
utilized in a phase I/II PRIT trial for patients with advanced lung cancer [67]. In this study focusing on
optimization, the importance of an imaging session beforehand was once again confirmed since this
was shown to be predictive for absorbed doses in therapy. Furthermore, the study determined that a
24 h delay and a peptide dose of 240 nmol/m2 were better pretargeting parameters for therapy than a
48 h delay and a 480 nmol/m2 dose.
2.2.2. Epithelial Cell Adhesion Molecule
The epithelial cell adhesion molecule (EpCAM) is a 40 kDa epithelial antigen that is expressed
on the surface of most human epithelial carcinomas (e.g., lung, colon, and breast). The NR-LU-10
murine monoclonal antibody recognizes this glycoprotein and is therefore the targeting vector of choice.
Axworthy et al. demonstrated improved efficacy of the pretargeting strategy using this monoclonal
antibody coupled to SA combined with a biotinylated galactosyl-human serum albumin clearing agent
in various cancer types, including SCLC, CRC and breast cancer [68]. A single dose of yttrium-90-labeled
DOTA-biotin resulted in 28/30 cures in mice bearing human SCLC, CRC, and breast cancer xenografts
as compared to 1/30 cures obtained with conventional RIT in these same animal models. The observed
therapeutic advances are most likely due to the >20-fold improvement in T:B ratio and increased absolute
tumor doses. Similar high cure rates were reached in the study of Goshorn et al., who additionally
showed that the use of an EpCAM-targeting FP is preferred over the normal monoclonal antibody [69].
The FP had a two-fold better antigen binding plus a faster blood clearance which in turn reduced blood
radioactivity exposure by four times.
The encouraging experimental results initiated a clinical phase I study in 43 patients with
adenocarcinomas [70]. In an optimized setting, PRIT with yttrium-90-labeled DOTA-biotin was able
to deliver a 63:1 tumor-to-bone marrow absorbed dose ratio, substantially higher than the 6:1 ratio
reported for conventional RIT. Coinjection of an indium-111-labeled tracer dose in a 1:50 ratio with
the yttrium-90-labeled tracer enabled the accurate estimation of these radiation absorbed doses.
The feasibility of the method that involved the quantification of the activity in gamma camera images
was previously described by Breitz et al. [71]. Subsequently, a phase II study was performed in
25 patients with metastatic colon cancer [72]. Treatment, however, appeared to be unsatisfactory in
terms of efficacy and both hematological and overall toxicity.
As became apparent from the observed toxicity levels, the therapeutic index was negatively
affected by the cross-reactivity of NR-LU-10 antibody with naturally expressing EpCAM tissues such as
the intestinal epithelium and kidney tubules. This underlines the importance of targeting antigens that
are highly expressed in tumor tissue but have no/little expression in healthy organs. In 2003 Lewis et al.
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published a preclinical study using the NR-LU-10 antibody, yet their goal was to encourage the use
of the intermediate half-lived radionuclide copper-64 (half-life = 12.7 h) [73]. The rapid pretargeting
approach enabled efficient delivery within ~1 h compared to ~48 h with direct targeting.
2.2.3. TAG-72
In contrast to NR-LU-10, the murine CC49 antibody directed against TAG-72 does not demonstrate
cross-reactivity with healthy tissues. TAG-72 is present on a variety of adenocarcinomas, but the utility
of PRIT is mainly validated in CRC. PRIT of subcutaneous human CRC xenografts using CC49 coupled
to SA and yttrium-90-labeled DOTA-biotin was proven to be safe when administered intraperitoneally
(i.p.) [74]. At least nine-fold higher doses were safely administered when compared to the application
of directly labeled yttrium-90 antibodies, but only a modest decrease of 30–40% in growth rate was
achieved. However, application of a pretargeting approach using FPs and the inclusion of an extra step
in which a synthetic clearing agent with multiple N-acetyl-galactosamine residues coupled to biotin was
introduced, showed significantly improved survival from 37 days for controls to 60 days for animals
treated i.p. with lutetium-177-labeled DOTA-biotin [75]. A phase I clinical study in chemoresistant
TAG-72 positive metastatic CRC patients with a CC49 FP and yttrium-90-labeled DOTA-biotin presented
eight- to 11-fold increased T:NT ratios with an impressive 139:1 tumor-to-bone marrow ratio [76,77].
The enhanced biodistribution was unfortunately accompanied by immunogenicity and thus therapy
was restricted to a single cycle.
The idea of using SA-coupled CC49 fusion proteins for PRIT purposes was rejected due to the
observed immunogenicity of SA. Therefore, alternative approaches have been invented such as CC49
PRIT by MORF/cMORF pretargeting which resulted in temporary complete responses in 3/5 human CRC
xenografted mice [78]. Interestingly, targeting of CC49 was shown to be equally effective as anti-CEA
PRIT in a CRC animal model. A follow-up study comparing rhenium-188- with yttrium-90-conjugated
cMORF detected similar tumor retention and clearance for both radionuclides. Exploiting the longer
half-life of yttrium-90 was considered to be beneficial since it would provide higher T:NT absorbed
dose ratios [79].
A comparison between radionuclides for PRIT with CC49 FPs was first carried out in 2004 where
analyses of the three radionuclides promethium-149, hollium-166, and lutetium-177 determined that the
best therapeutic index belonged to lutetium-177 [80]. This finding was later confirmed by Mohsin et al.
who also concluded that lutetium-177 was the optimal choice as it increased the median time to progression
from 13 to 50 days based on PRIT with tetravalent CC49 FPs [81]. In addition, five-times higher doses
than with conventional RIT could be safely delivered, resulting in more long-term survivors. Rossin et al.
used lutetium-177 and implemented this in their pretargeting method based on the IEDDA reaction in
another attempt to avoid immunogenicity and hence offering the possibility of repeated treatments [82].
When compared with conventional lutetium-177 RIT, PRIT boosted T:B ratios and allowed for eight-fold
higher tumor doses while decreasing toxicity. The potential of pretargeting for radionuclide therapy
using antibody fragments, which is often hampered by nephrotoxicity, was shown by van Duijnhoven et
al. [83]. A >20-fold higher tumor-to-kidney ratio was obtained with lutetium-177-labeled Tz and TCO
functionalized TAG-72-binding diabodies than with directly labeled diabodies.
2.2.4. Tenascin-C
Tenascin-C is an extracellular matrix protein abundantly expressed in the stroma of several solid
tumors such as melanoma and malignant glioma. For gliomas, tenascin expression is positively
correlated with tumor grade. Accordingly, PRIT with a biotinylated anti-tenascin antibody, followed by
avidin injection to provide binding sites for yttrium-90-labeled biotin was performed in 48 patients with
high-grade glioma [84]. This phase I/II clinical study demonstrated an objective tumor reduction and
disease stabilization accompanied by low toxicity in 25% and 50% of patients, respectively. As a result of
the promising therapeutic efficacy, the same pretargeting approach was evaluated in an adjuvant setting;
pretargeted therapy was started one month after conventional treatment [85]. Treated glioblastoma
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patients had a significantly longer survival time than control patients with a median survival of 33.5
versus 8 months, respectively. The same group continued treating numerous glioblastoma patients
with recurrent disease after standard treatments. A large scale retrospective study, analyzing data of
these 502 glioblastoma patients treated with tenascin-C-directed PRIT, reported a median survival of
19 months with 8% of patients showing tumor mass reduction and 28% presenting stable disease [86].
In accordance with other PRIT studies, high immunogenicity of SA was observed as almost all patients
(90%) developed anti-SA antibodies.
Since anti-tenascin monoclonal antibodies have been effective in intratumoral administration
of RIT [87], a phase I study was performed to evaluate whether applying a pretargeting approach
for locoregional RIT could also be of benefit. In 24 patients with recurrent glioma, therapy was
safely administered via a catheter, which was placed in the surgical resection cavity after the second
surgical debulking [88]. The response rates were in accordance with the previous phase I/II study. Even
higher tumor doses can be delivered when biotin conjugates are resistant to the enzymatic action of
biotinidase. Therefore, Urbano et al. designed a new biotin-DOTA conjugate to enhance PRIT efficiency
by preventing enzymatic degradation while maintaining high binding affinity for SA [89]. A pilot
experiment in metastatic melanoma patients showed favorable kinetics and high tumor uptake.
2.2.5. Other Solid Tumor Targets
Over the past decades, multiple solid tumor targets have been explored. In the early days of
pretargeted therapy, when the focus was primarily on demonstrating its potential, experiments were
performed using an antibody specific for yttrium-88-labeled DOTA that localized in the tumor via
passive diffusion through the leaky vasculature. Goodwin et al. were the first to apply this pretargeting
approach for RIT [90]. Supported by the previous development of the DOTA bifunctional chelator,
high selective tumor uptake and promising T:B ratios were obtained with PRIT using a large molecular
weight polyvalent hapten as clearing agent. A more thorough investigation into the biodistribution
and dosimetry of this approach determined high therapeutic ratios. This was particularly caused by
low blood and bone marrow doses as a result of the rapid clearance from all organs, and the stable
DOTA chelation reducing the amount of free yttrium-90 that could potentially accumulate in bone [91].
To avoid the choice of selecting the appropriate target, administration of a cocktail of three
different biotinylated antibodies, i.e., anti-TAG72, anti-CEA, and anti-tenascin, was investigated by
Cremonesi et al. [92]. The authors determined that patients with various tumors were able to withstand
higher activities using this strategy than with conventional RIT. Besides, the importance of stable
chelation was again confirmed as the difference between DTPA (with less stable chelation) and DOTA
revealed that unbound yttrium-90 was mainly responsible for observed hematopoietic effects. A different
combination of anti-MOv18 directed at the folate receptor α, anti-TAG72, and anti-CEA monoclonal
biotinylated antibodies and yttrium-90-labeled DOTA-biotin was well tolerated in 38 advanced ovarian
cancer patients when administered either i.p. or i.p. plus intravenously (i.v.) [93]. The fact that in a
relatively large percentage of patients tumor reduction or disease stabilization (9% and 32% respectively)
occurred was remarkable since all patients were no longer responsive to conventional treatments. This
implies that PRIT could function as an effective treatment for end-stage ovarian cancer patients.
The issue of the most advantageous target for PRIT or RIT and in this case specifically for SCLC,
was also addressed by Hosono et al. [94]. The authors stated that the neural cell adhesion molecule
(NCAM) could serve as a complementary target for SCLC, since CEA is only heavily expressed in <35%
of cases. Anti-NCAM × anti-histamine bsAb and radioiodinated bivalent hapten-based PRIT resulted
in higher T:NT ratios suggesting a dosimetry benefit for PRIT using bsAbs compared to treatment
with directly radiolabeled antibodies. Sato et al. evaluated mesothelin as target antigen, which is
overexpressed on mesotheliomas and ovarian cancers [95]. Although a high therapeutic efficacy was
observed with 86% more survivors after 110 days than in the untreated mice population, PRIT using
tetravalent FPs directed against mesothelin is challenging due to possible cross-reactivity with normal
mesothelin-expressing tissues (e.g., pleura, pericardium, and peritoneum). Another study focused on
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the Lewisy antigen, which is expressed on the cell surface of many different carcinomas [96]. In contrast
to RIT, the PRIT approach based on the avidin–biotin system using yttrium-90 resulted in good tumor
responses in mice xenografted with a human epidermoid carcinoma cell line [97].
Cheal et al. selected disialoganglioside (GD2) and glycoprotein A33 (GPA33) as targets for PRIT in
neuroblastomas and CRC, respectively. PRIT using an anti-GD2 × anti-DOTA scFv bsAb construct and a
lutetium-177-labeled hapten resulted in complete tumor responses in 5/5 animals carrying subcutaneous
human GD2 positive neuroblastoma xenografts treated with three successive cycles [98]. Similar
responses were seen for two-cycle anti-GPA33 PRIT with lutetium-177, but only 2/9 mice bearing human
CRC xenografts showed no recurrence after >140 days [99]. After immunohistochemical analysis of
the residual tumors, it was concluded that tumor regrowth was likely because of insufficient radiation
absorbed doses to the tumor rather than a decrease in target expression. The addition of a third cycle to
the fractionated regimen proved to be essential for cure [100]. Van Rij et al. also investigated the potential
of multiple cycles of PRIT, but used a trophoblast cell-surface antigen 2 (TROP-2) positive prostate cancer
model. They showed no additional benefit of three cycles of PRIT using a lutetium-177-labeled peptide
compared to RIT; PRIT was at least as effective with similar hematological toxicity [101]. However, these
results are not in line with results generally obtained in preclinical PRIT studies and can be assigned
to the decreased tumor affinity of the anti-TROP-2 bsAb used in this study. This clearly indicates the
importance of choosing a good vehicle in addition to a suitable target.
Traditionally, it was understood that a non-internalizing target provided better accessibility for
the secondary agent. This understanding has recently been challenged by studies demonstrating the
feasibility of PRIT for internalizing HER2 receptor complexes in breast cancer. Though it was shown
by Van Rij et al. that high and fast accumulation can be achieved with internalizing anti-TROP-2
bsAb-antigen complexes [102], the first case of curative and safe fractionated PRIT was reported by
Cheal et al. [103]. Anti-HER2 × anti-DOTA-Bn bsAb and lutetium-177-labeled hapten based fractionated
3-cycle PRIT resulted in successful tumor targeting of HER2 positive BT-474 human breast cancer
xenografts (Figure 3) and demonstrated successful antitumor efficacy. Another study that focused
on anti-HER2 PRIT used an affibody-based peptide nucleic acid pretargeting strategy. Using this
pretargeting strategy, anti-HER2 PRIT with lutetium-177 has also been shown to improve survival in
mice bearing HER2-expressing human xenografts and has overcome the problems of renal toxicity
normally associated with affibodies [104].
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The GPA33 and the pancreatic ductal adenocarcinoma (PDAC) biomarker carbohydrate antigen
19.9 (CA19.9) have been explored for bioorthogonal click chemistry-based PRIT. After promising results
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with this approach during imaging and biodistribution studies, Houghton et al. were the first to perform
a longitudinal therapy study [105]. Pretargeted therapy with a TCO-modified anti-CA19.9 antibody and
different doses of lutetium-177-labeled Tz illustrated a dose dependent antitumor effect with the highest
dose of 1200 mCi resulting in effective tumor regression in 6/8 mice bearing human PDAC xenografts.
A dosimetry study by Membreno et al. showed that the effective dose of an IEDDA based anti-huA33
PRIT also with lutetium-177-labeled Tz in human CRC bearing mice was only marginally lower than
with conventional RIT (0.054 vs. 0.068 mSv/MBq) [106]. However, the dose delivered to the normally
dose-limiting bone marrow was nearly halved, thus allowing treatment intensification of PRIT.
Recent innovations have led to the possibility to create a local tumor target for targeted radionuclide
therapy in an intraoperative setting. The injection of avidin into and around the tumor bed prompts
‘avidination’ of the tissue; avidin serves as an artificial receptor. A proof-of-principle study in 11 breast
cancer patients confirmed homing of i.v. administered yttrium-90-labeled biotin to avidin in the tumors
which resulted in fast and stable uptake of radioactivity [107]. The oxidized form of avidin (avidinOX)
possesses a longer tissue residence time than native avidin. In this setting, the use of avidinOX and
subsequent therapy with yttrium-90-labeled biotin resulted in eradication of neoplastic breast cancer
lesions in mice [108]. Albertoni et al. focused on the application of avidinOX for local treatment of tongue
cancer masses, thereby illustrating its potential utility for unresectable tumors [109]. This approach
produced significant antitumor activity whilst preserving the integrity and function of healthy tissue.
3. Pretargeted Alpha-Particle Therapy
The choice of radionuclide has considerable impact on the effectiveness of targeted radionuclide
therapy. The use of alpha particles as the cytotoxic agent could offer significant advantages over beta
particles for treatment of metastatic or minimal residual disease because of the short path length in
tissues (<100 µm) and high linear energy transfer (~100 keV/µm) of these particles. Beta particles have
a lower energy transfer compared to alpha particles, and cause DNA damage mostly via an indirect
effect. This is in contrast to the direct DNA damage induced by alpha particles, which is independent
of the formation of reactive oxygen species. In contrast to the single strand DNA breaks caused by beta
particles, DNA double-strand breaks caused by alpha particles are harder to repair and therefore more
frequently result in cell death. Concerning the range, beta particles penetrate more easily through
tissue which could be beneficial in case of tumor heterogeneity, but in case of small tumor lesions,
a large fraction of their energy is deposited outside the tumor area. For this reason, targeted alpha
therapy is considered to achieve a higher therapeutic efficacy for microscopic tumors. Pretargeting
strategies compatible with two promising alpha emitters bismuth-213 and astatine-211, possessing
short half-lives of 46 min and 7.2 h respectively, were introduced. Park et al. showed that directly
labeled antibodies with bismuth-213 were not effective in delivering radioactivity to the tumor because
most radioactive decay occurred in the bloodstream [110]. The application of a pretargeting strategy
improved RIT using this alpha-emitting radionuclide. The authors demonstrated that alpha PRIT
directed against CD20 significantly prolonged survival in mice bearing human lymphoma xenografts.
Alpha PRIT directed against CD25 can play an important role in addressing isolated malignant
cells often present in leukemia. This highly localized treatment is especially advantageous for cells
critically located in the bone marrow. Besides the benefit of a pretargeting approach, here, the use of
short-range alpha-particles emitted by bismuth-213 prevent adverse effects as a result of hematopoietic
stem cell irradiation [111,112]. Pagel et al. also showed the potential of bismuth-213 alpha PRIT. In their
study, anti-CD45 alpha PRIT proved to be 60% more effective than PRIT with beta-particle irradiation
for treatment of AML while minimizing toxicity [113]. Next to leukemia, attention has been paid to the
role of alpha PRIT with astatine-211 for intracavity treatment of disseminated ovarian microtumors.
Although therapy directed at the membrane transporter SLC34A2 was injected i.p. and thus not
influenced by the prolonged circulation time of antibodies, the limiting factor in this case was the slow
tumor penetration compared to the radionuclide half-life. In this situation, pretargeting with small
molecules was successfully applied to achieve a faster and more homogeneous biodistribution [114,115].
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Debate continues about the best choice of alpha-emitting radionuclide for alpha PRIT. Astatine-211
is considered best at delivering high tumor doses to CEA-expressing lesions as deduced from
pharmacokinetic modeling [116]. It has become apparent from previous studies that in contrast
to the hematologic toxicity of conventional RIT, the main limitation of alpha PRIT is the risk of
nephrotoxicity [117,118]. Several alternative strategies have been suggested to reduce nonspecific
radioactivity uptake in the kidneys, such as adjusting the charge and size of the small molecule [119],
an oral administration route [110], chelate therapy [120], dose fractionation, or the use of longer lived
radionuclides to reduce the percentage of decay in the kidneys. Recently, investigators have examined
the use of the longer lived alpha-particle emitting radionuclide, actinium-225, for pancreatic ductal
adenocarcinoma. However, here, the release of radioactive unbound daughter nuclides with intrinsic
off-target kidney affinity might complicate clinical translation [121].
4. Combination Therapy
The past decades have seen increasingly rapid advances in the field of combination therapy for
cancer management. For instance, chemoradiotherapy is now an established treatment approach. Of
particular concern is the increase in toxicity when combining two treatment modalities. Since pretargeted
therapeutic strategies have been designed to lower the toxicity of RIT, particularly hematologic
toxicity, they are interesting to combine with other anticancer treatments such as myelosuppresive
chemotherapeutics, or to serve as adjuvant care. It has been illustrated that the antitumor efficacy of
PRIT can be enhanced in a synergistic manner by applying radiosensitizing chemotherapeutic drugs
like paclitaxel [122] or gemcitabine [123,124]. The use of PRIT in combination therapy has also been
shown to be effective in eradicating residual disease. Either in combination with the alkylating agent
temozolomide, microscopic disease outside the radiation field of locoregional PRIT was eliminated [125],
or PRIT was used in an adjuvant setting after surgery and radio-chemotherapy [126]. Moreover,
administration of immunotherapy directed against the same target after PRIT has been shown to
produce an enhanced antitumor response [111,127].
5. Novel Applications of Pretargeting: Beyond Antibodies as Targeting Vector
Nanocarriers, such as liposomes and nanoparticles (NPs), have emerged as promising vehicles for
cancer-targeted drug delivery. Encapsulating therapeutic molecules facilitates the use of hydrophobic
anticancer drugs and more importantly maximizes the dose that can be deposited, which in turn
improves the therapeutic efficacy. The carriers preferentially accumulate in tumor tissues by the
enhanced permeability and retention (EPR) effect due to the characteristic leaky vasculature of tumors
and insufficient lymphatic drainage. Apart from this so-called passive targeting, active targeting using
carriers functionalized with tumor targeting ligands has been explored to enhance disease specificity
and decrease systemic toxicity. However, because of the poor circulation kinetics and the rapid clearance
of these carriers, tumor delivery is not markedly improved when actively targeting carriers are applied
compared to passive accumulation from nontargeted carriers. As a result, the therapeutic index remains
limited thus indicating the need for alternative strategies such as pretargeting. A pretargeting strategy
using bsAbs and biotinylated liposomes loaded with technetium-99m-labeled DTPA improved targeting
by four times, illustrating its possible use for selective delivery [128]. As a side note, the composition of
liposomes can substantially influence the ability of biotinylated liposomes to bind SA [129].
One of the chemotherapeutic drugs identified by many researchers to substantially benefit
from a pretargeted drug delivery system is doxorubicin (DOX). I.p. administration of SA decorated
DOX-loaded liposomes resulted in a 3.7-fold increase in drug localization to the pretreated tumor site
versus control liposomes [130]. The benefit of i.p. administration over i.v. injection for liposomal DOX
carriers targeting i.p. inoculated tumors was also shown by Lehtinen et al. [131]. In the same study,
the authors compared pretargeting vs. direct targeting vs. nontargeted liposomes, but this did not
show any additional benefit of a pretargeting approach or targeting in general. For tumor necrosis
treatment with DOX, however, pretargeting does seem to have potential. Here, treatment based on
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the biotinylated form of an antibody directed against degenerating cells located in tumor necrotic
regions and SA modified liposomes as DOX carrier resulted in inhibited tumor growth within the first
few days [132]. Khaw et al. tested a different approach to enhance tumor specificity by conjugating
DOX to a polymer functionalized with DTPA to form a polymer prodrug conjugate that can bind to
previously injected bsAbs directed against HER2 and DTPA [133]. Although the therapeutic efficacy
was equivalent in HER2 positive human mammary carcinoma bearing mice pretargeted with a bsAb
complex or treated with DOX only, the toxicity was significantly less as no total body weight loss
was recorded for the pretargeted subgroup. This highlights the high target specificity of this method
and its ability to increase the therapeutic index of DOX by overcoming the major limitation for its
use: cardiotoxicity.
Tumor necrosis factor (TNF) receptor ligands were originally also recognized to have a strong
antitumor potential, yet their poor tumor selectivity resulted in major side effects. A first attempt to
increase the tumor concentration of TNF-alpha by means of pretargeting was done by Moro et al. in
1997 [134]. They pretreated cells in vitro with biotinylated antibodies followed by avidin to provide
extra binding sites for the thereafter administered biotin-TNF prior to injection of those cells into mice.
Consequently, mice bearing mouse mutant lymphoma xenografts appeared to be less tumorigenic,
showing the potential of pretargeting to increase the binding and residence time of TNF on tumors.
In vivo pretargeting with biotin-TNF increased the antitumor activity by at least five times without
adding to the toxicity levels [135]. Tarrus et al. showed that a pretargeting approach with biotinylated
recombinant TNF-related apoptosis-inducing ligands (TRAILs) targeting RGD-avidin, bound on
angiogenic endothelial cells via the αvβ3 integrin receptor, enhanced tumor cell death even further
through increased tumor accumulation of these ligands [136].
For B-cell malignancies, apoptosis induction can be established by crosslinking CD20 at the surface
of B-cells. A pretargeted nanotherapy using anti-CD20 antibody fragments conjugated to MORFs
followed by the injection of polymer backbones decorated with multiple complementary MORFs
significantly enhanced the pro-apoptotic activity compared to immunotherapy with the anti-CD20
antibody Rituximab alone [137]. Furthermore, this CD20 cross-linking amplification based on MORF
pretargeting could be used to overcome the resistance to Rituximab [138]. Functionalized nanocarriers
can also play a pivotal role in overcoming induced drug resistance. For example, patients resistant to
the anti-HER2 monoclonal antibody trastuzumab could benefit from prelabeling their HER2 receptors
with trastuzumab conjugated to a binding moiety for drug-loaded nanocarriers to still affect HER2
positive cells [139].
A delivery vehicle can additionally be utilized to carry high activity doses of radionuclides.
To enable, for example, imaging of DOX-induced cardiotoxicity in small animals, nanocarrier pretargeting
can be applied to localize a high specific radioactivity particularly at the target site [140]. Double labeling
of nanocarriers such that the radioactivity load is distributed over the membrane and the inner aqueous
phase, as was done by Rauscher et al., can further increase the deposited doses [141]. Liposomes also
offer the opportunity to transport Auger-electron-emitting radionuclides into the cell nucleus to get
them in close vicinity to DNA where they are cytotoxic. Using a HER2-directed pretargeting approach,
a 70% survival was reached demonstrating the potential of pretargeting with Auger-electrons [142].
In some cases, passive NP targeting still has its advantages. Delineation of tumor margins
with positron emission tomography can be established as a consequence of the accumulation of
radiopharmaceutical liposomes via the EPR effect. However, due to long circulation time of liposomes,
long-lived radionuclides like zirconium-89 are necessary. Therefore, Brand et al. designed the so-called
on-demand bioorthogonal removal of circulating TCO-tagged liposomal NPs to decrease exposure to
nontargeted tissues and allow imaging at an earlier time point [143]. Most recently, pretargeting has
extended its application to the field of liver radioembolization. In this case, pretargeting is used to
better correlate the scout scan (a scan that is used to predict the intra- and extrahepatic distribution of
activity) to the therapeutic dose. Here, the strong interaction between cyclodextrin and adamantine
was employed; an alternative pretargeting method [144,145].
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In recent years, there has been an increasing interest in introducing artificial receptors on tumors by
means of metabolic glycoengineering. This technique involves cell treatment with metabolic precursors
in the form of unnatural monosaccharides containing azido groups. These azido groups are inserted
into the surface glycan via the intrinsic metabolic pathway of the cell, making azido groups available
for dibenzocyclooctyne (DBCO) to bind. Combining bioorthogonal chemistry (i.e., the copper-free click
chemistry reaction between an azido group and DBCO) with this cell surface labeling strategy enables
cell targeting by functionalized NPs with high efficiency. Pretargeting via metabolic glycoengineering
is shown to be dose-dependent, meaning that binding of the functionalized NP can be controlled
by changing the concentration of the metabolic precursor injected into the tumor [146]. Layek et al.
provided evidence of the tumor specificity of this method and illustrated its potential to significantly
inhibit tumor growth and improve survival in an orthotopic metastatic ovarian tumor model when
administering glycoengineered mesenchymal stem cells and paclitaxel-loaded functionalized NPs [147].
The artificial chemical receptors presenting azido groups for bioorthogonal click chemistry can also
be generated in vivo by enveloping the metabolic precursors in NPs and letting the localization in
targeted tumor tissue be guided by the EPR effect [148]. The feasibility of a reversed approach by
generating large-sized DBCO groups on tumor cells in contrast to the previously used small-sized azido
groups for cell labeling was demonstrated by Wang et al. [149]. The authors also clearly illustrated the
benefit of pretargeting via metabolic engineering over passive targeting through the EPR effect for
tumor accumulation of nanoconjugates (Figure 4). Introducing receptor-like Tz groups has also been
shown to significantly enhance NP tumor targeting [150]. Artificially installing receptors is a way to
overcome tumor heterogeneity and the limitation of low numbers of biological receptors available for
targeted therapies. Alternatively, Yang et al. considered a dual targeting approach to deal with tumor
subpopulations using a cocktail of anti-CD20 and anti-TAG-72 FPs to attract biotinylated NPs [151].
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6. Conclusions and Perspectives
Pretargeting has been shown to be a feasible and a pro ising strategy for therapeutic purposes.
PRIT has proven to be superior over RIT in ter s of ore favorable T:B ratios, reduced toxicity, and
i proved efficacy. The low toxicity profile of PRIT allowed for treat ent intensification, as higher
axi u tolerated doses could be safely ad inistered, and was therefore particularly suited to be
part of a co bination therapy regi en. As a result of the i pressive results obtained with PRIT, the
use of pretargeting has expanded to alpha-particle therapy and drug delivery syste s. The scope of
pretargeting will grow further now that internalizing targets have presented the selves as potential
targets. The success of treat ent is largely dependent on tu or antigen expression; hence, i aging
beforehand could assist, encouraging the application of pretargeting strategies for theranostic applications.
The importance of choosing a suitable target was further underlined by the cross-reactivity with off-target
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tissues observed for e.g., EpCAM-directed PRIT. The technique to introduce artificial receptors on cell
surfaces provides an alternative when target cells lack appropriate molecular biomarkers. Furthermore,
pretargeting with smaller targeting constructs has shown less toxicity due to faster clearance and better
binding, thereby decreasing the risk of nephrotoxicity normally seen for small fragments. The future
will have to show whether this will drive the development of smaller targeting compounds such as
peptides for pretargeted therapy as well.
Despite its immense promise, pretargeted strategies have not yet been implemented in the clinic.
This is mostly due to the lack of an appropriate bioconjugation technology. Over the years, different
pretargeting techniques have emerged, and each proved to have advantages and disadvantages. Overall,
the avidin–biotin system has been studied most frequently in both preclinical and clinical studies.
An important advantage of this method is the high binding affinity of biotin for SA. In addition, SA has
four binding sites for biotin, which, together with the high binding affinity, results in high and persistent
tumor uptake. However, this system is hampered by drawbacks in the form of immunogenicity evoked
by SA, and the in vivo stability of biotin which is dependent on biotinidase activity and the competition
with endogenous biotin. Apart from the avidin–biotin system, a lot of clinical research has been
performed with bispecific antibodies, mostly directed at CEA. These studies marked the need for
fully humanized constructs to avoid a significant human anti-mouse antibody response induced by
murine and chimeric constructs. In this case, the complex production and costly process is a major
disadvantage hampering clinical translation. In addition, as a consequence of the reversibility of
the bispecific antibody–hapten interaction, a generally lower tumor uptake is observed with this
pretargeting method compared to the other methods.
The newer pretargeting methods based on complementary oligonucleotides and bioorthogonal
click chemistry might offer solutions for the primary drawback of the avidin–biotin system and the
use of bispecific antibodies, because these methods do not interfere with biological processes and
therefore evade immunogenicity. A potential disadvantage of using complementary oligonucleotides
for pretargeting is the limited in vivo stability of these constructs. However, PRIT using this emerging
strategy is currently only studied at the preclinical stage and methods are being developed to overcome
this limitation. When it comes to bioorthogonal click chemistry, a major advantage of this method is
that the reactions are selective, fast, and efficient. To date, clinical studies using this method have not
been performed, but results of preclinical studies are promising.
The challenge of pretargeting being a multistep process makes it more difficult and costly to
develop, but the fact that PRIT can provide a treatment option for chemoresistant or end-stage patients
illustrates that it is worthwhile to improve the pretargeting technology. Moving forward, without
doubt, new strategies will be explored that will in turn stimulate the use of pretargeting in novel ways.
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